ENDPOINTS-11 BIOPHARMA’S MOST PROMISING STARTUPS 2023’

 INDIA – At the Endpoints News Awards in Boston, USA, Immuneel Therapeutics, India’s leading clinical-stage cell and gene therapy startup, was named and awarded amongst ‘Endpoint-11 Biopharma’s Most Promising Startups 2023’. The event annually honours the top 11 global biopharma startups after rigorous peer review research. This esteemed award not only underscores Immuneel’s significant contributions towards transforming cancer care with innovative and affordable treatments but also positions the company as a global advocate for equitable access. Immuneel is the first startup from India to receive this award.

Endpoints citation read, (excerpted), “It’s not often that a startup biotech puts an emphasis on commercial innovation and making drugs affordable to the developing world. The Indian biotech Immuneel Therapeutics is on the verge of a grand commercial challenge to the drug industry, aiming to bring cell and gene therapies to the rest of the world at a fraction of current prices. As Immuneel waits for Indian regulators on what could be the country’s first CAR-T therapy, its leaders are also looking ahead. The company is developing its own pipeline of cell and gene therapies, likely to divulge more details over the next year or so. And Immuneel hopes to bring this model to more low- and middle-income countries that would otherwise have no access to these advanced therapies”.

Commenting on this award, Ms Kiran Mazumdar Shaw, Co-Founder & Director, Immuneel Therapeutics, said, “We are delighted and proud to be recognised in this super-select club of 11 most ambitious start-ups on the global biotech stage. It was our vision as co-founders of Immuneel, to place India on the CAR-T map, and this acknowledgement goes a long way in affirming our focus to bring affordable transformative cell therapies to India and the world.”

Immuneel aims to disrupt the landscape of cancer treatment in India and beyond and make cell therapies accessible to the patients, while maintaining global standards. Speaking on this global recognition, Dr Arun Anand, Director & Chief Operating Officer, Immuneel Therapeutics reacted, “This award is a breakthrough moment for Immuneel as well as for India’s biopharma industry. This recognition comes at a time when the biotech industry in India is transforming to be a global force and Immuneel is playing a pivotal role in reshaping the paradigms of cancer treatment through innovation. We extend our gratitude to Endpoints News for this honour.”

Personalized cell therapies are in their nascent stage and Immuneel is playing to be a differentiator in this domain through innovation and collaboration. Dr Siddhartha Mukherjee, Co-founder & Director, Immuneel Therapeutics, added, “Treatment with CAR-T therapies costs upwards of a million dollars in US. Through Immuneel’s efforts, we are committed to see that patients in India have access to global quality CAR-T treatment at a fraction of this cost.”

On receiving the award at the ceremony, Dr Kush Parmar, Co-founder, Immuneel Therapeutics, expressed his gratitude and said, “As we advance in our mission to provide transformative therapies to patients in India and beyond, this award positions us as one of the top 11 startups and the only one looking to create a meaningful impact to cancer patients in regions without access to CAR-Ts. Receiving this award is matter of pride and joy, it acknowledges the hard work put in by everyone at Immuneel to have traversed the journey from inception to clinical data in just 4 years.”